1. Introduction {#s0005}
===============

A vast biology is associated with action at the G protein-coupled adenosine receptors (ARs) and P2Y receptors and at ionotropic P2X receptors, which is modulated by all of the nucleoside and nucleotide processing enzymes and transporters. This extensive signaling system is qualified to be considered part of the 'purinome' [@bb0005], a term already applied in the context of the \> 3200 proteins that utilize purine cofactors, including intracellular kinases [@bb0010], as well as to describe the actions of extracellular and intracellular purines (and pyrimidines) in this collection of related receptors and enzymes.

The release of ATP, UTP and other nucleotides by various routes from cells results in a temporal sequence of activation of these three families of cell surface receptors [@bb0015]. The receptors activated initially are the fast P2X ion channels (ATP-responsive trimeric channels composed of seven distinct subunits) and some of the metabotropic P2Y receptors (i.e. P2Y~2~, P2Y~4~ and P2Y~11~Rs that respond fully to nucleoside 5′-triphosphates and P2Y~14~R that responds to UDP-sugars). Upon the sequential action of ectonucleotidases CD39 (ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1) and CD73 (ecto-5′-nucleotidase, 5′-NT) [@bb0020], different sets of receptors are activated (i.e. P2Y~1~, P2Y~6~, P2Y~12~, P2Y~13~ and P2Y~14~Rs that respond to nucleoside 5′-diphosphates), followed by the activation of four AR subtypes (A~1~, A~2A~, A~2B~ and A~3~ARs), which are not appreciably activated by any endogenous nucleotides. Naturally occurring dinucleotides, such as Up~4~A, are also known to activate various P2YRs [@bb0025].

A current challenge to medicinal chemists is to identify selective P2R agonist and antagonist ligands, which remains an unmet need for most of the P2XRs and many of the P2YRs. The effort to design purine receptor ligands is now aided by representative X-ray crystallographic structures in each of the three classes: A~2A~AR, P2Y~12~R and P2X4R [@bb0030; @bb0035; @bb0040; @bb0045; @bb0050; @bb0055]. Many more receptor structures in complex with different ligands will be needed to gain a detailed and broad knowledge of molecular recognition within these families. The high resolution G protein-coupled receptor (GPCR) structures and, to a lesser extent, homology models obtained so far have proven valuable for in silico screening campaigns [@bb0060; @bb0065]. Biophysical mapping of binding sites, lipophilic hotspots, explicit water networks and other techniques based on GPCR structures are now used for drug design [@bb0070]. Moro and coworkers validated a general pharmacophore hypothesis for the human A~2A~AR using an external test set of 29 newly synthesized antagonists [@bb0075]. Thus, we and others have demonstrated the predictive power of GPCR homology modeling and the value of applying newly determined X-ray structures to the medicinal chemistry of purine and pyrimidine GPCRs [@bb0055; @bb0060; @bb0065; @bb0070; @bb0075; @bb0080]. However, we are only at the beginning of exploring ligand design based on GPCR X-ray structures, and we are far away from predicting selectivity and function of ligands from such models.

In general, we establish detailed structure activity relationships in the purine receptor families, in order to provide selective agents as pharmacological probes and potential therapeutic agents. Our efforts to discover novel, selective ligands for purine receptors stem initially from the guidance and inspiration of John W. Daly, Ph.D. (1933--2008), a noted medicinal chemist and pharmacologist. He was one of those who defined the existence of receptors for adenosine and the biological effects of methylxanthines, by chemical and pharmacological means [@bb0085]. He emerged from the era in which many medicinal chemists were not yet accustomed to the idea of structure activity relationship (SAR), in which different functionality on a given molecule subserves distinct roles in receptor recognition. However, very early in the development of our field, Daly applied SAR analysis to the ARs to help define three of the four receptor subtypes and introduced important ligand tools, such as A~1~AR-selective *N*^6^-cycloalkyladenosines and 8-aryl- and 8-cycloalkyl-1,3-dipropylxanthines (with postdoctoral fellows R. F. Bruns and M. T. Shamim) [@bb0090; @bb0095]. Much of our study of the SAR of P2YRs has been in collaboration with T. Kendall Harden.

2. X-ray Structures of A~2A~ and P2Y~12~ Receptors With Bound Agonists and Antagonists {#s0010}
======================================================================================

2.1. Molecular Recognition at Adenosine Receptor Structures {#s0015}
-----------------------------------------------------------

The structure of adenosine consists of two chemically and conformationally distinct moieties, each of which is associated with separate roles in the AR orthosteric binding site(s). These two moieties can be divided into message (ribose) vs. address (adenine) portions. While adenine and similar flat, hydrophobic heterocycles often behave as AR antagonists, the addition of a ribose moiety at the appropriate position (adenine-9-ribosides or xanthine-7-ribosides) can confer the ability to activate the receptor, i.e. deliver the message by complementarity with the conformation of the AR protein required to induce its activation.

In some cases, the same substituents of the N^6^ and C2 positions of an isolated adenine AR antagonist maintain the same receptor subtype binding preferences that are found in riboside-bearing agonists (see A~1~ and A~3~AR ligands **1**--**10** in [Table 1](#t0005){ref-type="table"}), suggesting a common mode of receptor binding. The affinity of the AR agonists is generally much greater than the corresponding adenines, because the ribose anchors and stabilizes the bound ligand. Although the AR subtype selectivity of the lone nucleobases has much commonality with the SAR of adenosine agonists, it is not identical [@bb0100; @bb0105; @bb0110; @bb0115; @bb0120]. For example, in a study of 2-, 6- and 8-substituted adenines, Klotz et al. [@bb0110] noted a pharmacological similarity between C2 substitution in adenosine and 8-substitution in adenine. No AR structures containing an unmodified adenine antagonist have been determined yet, but the positions of other AR antagonists in crystal structures so far indicate a similar hydrophobic binding region (either a close overlay of a 1,2,4-triazolo\[1,5-*a*\]\[1,3,5\]triazine with the adenine of agonists or non-superimposed rings for xanthines) [@bb0030; @bb0125]. π--π Stacking of the nucleobase rings with a conserved Phe in extracellular loop (EL)2 and often H-bonding with a conserved Asn (6.55, using Ballesteros--Weinstein numbering [@bb0130]) are typically common to agonists and antagonists in the A~2A~AR structures and in models of the other AR subtypes.

Because the ribose moiety constitutes the message portion of adenosine agonists, we have focused on its conformational characteristics at the ARs and also at P2X and P2YRs. From the X-ray structure of the human A~2A~AR containing a bound nucleoside ([Fig. 1](#f0005){ref-type="fig"}A) [@bb0035], we now understand that the ribose moiety fits in a deep subpocket of the ARs, where it activates the receptor by drawing hydrophilic residues in transmembrane helices (TMs) 3 and 7 toward it, like the tightening of a belt. The ribose of adenosine agonists is coordinated by H-bonding to conserved residues Thr (3.36), Thr or Ser (7.42) and His (7.43) [@bb0035; @bb0135; @bb0140]. At the same time, the binding of ribosides is driven entropically by the displacement of unstable water molecules in this region. Departure of unstable water molecules also can contribute to the binding of AR antagonists [@bb0070; @bb0145]. Although it lacks a G protein or G protein mimic, the agonist-bound A~2A~AR structure by Xu et al. [@bb0035] displays intracellular features that resemble other activated GPCR structures. This complex contains a bound 6-(2,2-diphenylethylamino)-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-*N*-(2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)ethyl)-9*H*-purine-2-carboxamide (UK432097), a failed experimental drug for treatment of chronic obstructive pulmonary disease. Thus, the agonist-induced contraction of the ribose-binding region of the A~2A~AR appears to be propagated to the cytoplasmic side of the receptor that is in contact with the G~s~ protein (as demonstrated structurally for the β~2~-adrenergic receptor [@bb0150]). This conformational adaptation to agonist is likely to be similar but not identical at the other AR subtypes.

Prior to the X-ray structural determination, we sought to define the receptor-preferred conformation of the ribose ring chemically by introducing steric constraints on the native, freely-twisting ribose moiety by fusing two small carbocyclic rings. The methanocarba (bicyclo\[3.1.0\]hexane) ring system (fused cyclopropyl and cyclopentyl rings) freezes opposite twists of a ribose-like moiety (either (N), North or (S), South envelope conformations) when incorporated into nucleoside/nucleotide analogues with the bond of ring fusion at either of two positions [@bb0155]. These modifications can enhance or reduce potency at different subtypes of purine receptors in comparison to the ribose moiety [@bb0155]. These ribose modifications, applied across the entire family of receptors, have been particularly potency-enhancing at certain subtypes, for example (N)-methanocarba at the A~3~AR [@bb0365]. Compounds **7** and **9** in [Table 1](#t0005){ref-type="table"} contain a potency- and selectivity -enhancing (N)-methanocarba ring. The effects of an (N)-methanocarba substitution on affinity at the A~1~ and A~2A~ARs is variable, depending on other substitution of the nucleoside. Another effective means of enforcing a (N) or (S) conformation of the ribose was the addition of a methyl group to the 2′- or 3′-ribose carbon [@bb0160]. The X-ray structure of the agonist-bound A~2A~AR confirmed the presence of a (N)-ribose conformation [@bb0035]. Nevertheless, the general (N) conformation of ribose represents a range of geometric parameters [@bb0165], and the conformational requirements for ribose might differ slightly between AR subtypes. Without a crystal structure of the A3AR, we lack the detail of the ribose binding region needed to explain the greater preference of (N)-methanocarba analogues at the A3AR compared to other AR subtypes.

[Fig. 2](#f0010){ref-type="fig"}A shows a progression of structural changes from prototypical agonists **11**--**13** leading to enhanced A~3~AR selectivity, including (N)-methanocarba (**15**--**18** and **23**--**25**) and 4′-thio (**14**) [@bb0170] agonists. Either the reduction of H-bonding ability of the hydrophilic 5′-carboxamide (including by 4′-truncation for its complete removal, **20**--**22** and **26**--**28**) or the introduction of rigidity of the ribose moiety, as in spirolactam **19** [@bb0175], tends to convert agonists into antagonists (or at least partial agonists) with the retention of A~3~AR selectivity.

Novel fluorescent derivatives of high affinity GPCR ligands are useful tool compounds for characterization of receptors and their oligomeric assemblies. Fluorescent probes are useful for characterization of GPCRs in living cells by microscopy or flow cytometry or in cell membranes. Fluorescent agonists but not antagonists are highly internalized, consistent with the general phenomenon of agonist-induced GPCR internalization. A (N)-methanocarba modification together with a 2-ethynyl group was incorporated in a highly selective A~3~AR agonist fluorescent probe, MRS5218 **18** (K~D~ 31 nM), which was useful for flow cytometry of whole cells expressing the A~3~AR [@bb0180]. This probe contains an amide-linked Cy5 (cyanine) fluorophore.

2.2. Molecular Recognition at P2YR Structures {#s0020}
---------------------------------------------

In collaboration with Ray Stevens, Qiang Zhao, Christa Müller and colleagues [@bb0040; @bb0045], we analyzed the X-ray structure of the human P2Y~12~R (the first high resolution structure of any P2YR), an important antithrombotic target that is the site of action of three drugs already on the market. Three compounds used clinically: two irreversibly binding thienopyridines (clopidogrel and prasugrel), which are actually prodrugs of reactive thiols, and one reversible nucleotide-like antagonist, actually a nucleoside (tigcagrelor) [@bb0185]. The P2YRs belong on the δ-branch of GPCRs, which has only one other known structure for comparison, i.e. PAR1, another platelet receptor [@bb0190]. The antagonist-bound crystal structure of P2Y~12~R contained an experimental non-nucleotide antagonist from Astra Zeneca, AZD1283 **29** ([Fig. 3](#f0015){ref-type="fig"}), an ethyl 6-aminonicotinate sulfonylurea [@bb0040; @bb0195]. A benzyl moiety on AZD1283 displaces outwardly the position of TM6 with respect to the agonist-bound P2Y~12~R structure ([Figs. 1](#f0005){ref-type="fig"}B and [3](#f0015){ref-type="fig"}A) [@bb0045]. Several unusual features of the P2Y~12~R were noted, including a bifurcated binding pocket ([Fig. 3](#f0015){ref-type="fig"}B) and an extended and linear TM5. TM5 in most Family A GPCRs has a proline, which is associated with a kink in the helical structure. The extension and linearity of TM5 leads to the previously termed conserved disulfide bridge between TM3 and EL2 to be undefined in the AZD1283 structure and likely cleaved. Thus, it appears that this disulfide is dynamic in P2Y~12~R and may not be essential for the overall integrity of the receptor structure.

Also, the structures of P2Y~12~R complexes with a bound agonist 2-methylthioadenosine 5′-diphosphate (2-MeSADP **30**) and a bound partial agonist (2-MeSATP) were determined [@bb0045]. The first antagonists identified for this receptor were nucleotides (2-MeSATP and other ATP derivatives), but it appears that some of these have agonist properties [@bb0200], which is consistent with the close overlay of 2-MeSATP with 2-MeSADP in the receptor structures. The only binding feature in common between AZD1283 and the nucleotides is π--π stacking of Tyr105 (3.33) with aromatic rings, a cyanopyridine and adenine, respectively.

A comparison of nucleotide-bound and nonnucleotide-bound complexes of the P2Y~12~R illustrates unprecedented divergence of structure for stable complexes of the same receptor. The negatively charged nucleotide ligands are surrounded by at least 7 cationic residues in the loop regions and the outer portions of the helices, which are highly positively charged. This draws the ELs and the top portions toward the nucleotide ligands, which are almost completely enclosed. The phosphate moiety of **30** is coordinated by cationic and H-bonding residues in the N-terminal segment (through water molecules), in TMs 3, 6 and 7 and in EL2. It is to be noted that this agonist-bound P2Y~12~R structure does not display typical intracellular features of activated GPCR structures, so it is considered an inactive state of the receptor. Nevertheless, the ligand binding pocket and the extracellular regions are informative concerning conformational adaptation of the structure to accommodate nucleotides. There are five other pairs of GPCRs in agonist-bound and antagonist-bound states [@bb0205], and the P2Y~12~R shows the greatest divergence of all these paired structures.

A cartoon representing the progressive opening of the P2Y~12~R structure depending on the nature of the bound ligand is shown in Zhang et al. [@bb0045], with the nucleotide agonists (closed) and the nonnucleotide antagonists (open) as the extremes. The nonnucleotide antagonist binds to a widely opened binding site (even in comparison to PAR1), which consequently is free of the steric constraints of the loops that are drawn toward the negatively-charged ligands. Some of the nucleotide-mimetic antagonists, such as Cangrelor [@bb0210], are predicted to bind with a similar conformation to **30** while other bulkier antagonist derivatives do not dock readily into the 2-MeSADP or 2-MeSATP complexes, because the binding site is too contracted. Thus, a possible displacement of parts of the TM region is proposed in order to fit these antagonists. We are currently modeling binding at the P2Y~12~R to establish energetically favorable docking modes of other known ligands, both agonists and antagonists.

The divergence of the A~2A~AR and P2Y~12~R structures emphasize that these are two very different receptor classes. In the nucleoside and nucleotide-bound structures of these two receptors, respectively, the adenosine moiety is flipped ([Fig. 1](#f0005){ref-type="fig"}). Thus, in the P2Y~12~R, the adenine base, not the ribose occupies a deeper portion of the binding site, which now has a hydrophobic character [@bb0035; @bb0045].

3. Structure-based Design of Novel A~1~, A~2A~ and A~3~ Adenosine Receptor Agonists {#s0070}
===================================================================================

3.1. Design of Ligands Based on the X-ray Structures {#s0075}
----------------------------------------------------

For the structure-based design of new AR nucleoside ligands, each portion of the adenosine molecule requires a different approach for derivatization; no single approach is general for all applications. A~2A~AR crystallographic structures are effectively applied to homology modeling of the closely related A~1~AR and A~3~AR, which are not yet crystallized. Based on the X-ray structure of the A~2A~AR [@bb0035], the C2 position is located in an approach path that easily frees itself from the constraints of the pharmacophore binding region to exit the receptor. This opening to the extracellular medium explains why the elongation of chains at the C2 position, for example by peptide or polymeric moieties, was found empirically to be allowed in receptor binding. The N^6^ region is slightly more constrained spatially than the C2. We have probed the tight fit of various hydrophobic N^6^ substituents at the ARs, thus explaining the early observations concerning stereochemistry at the α-carbon, for example that R-*N*^6^-(phenylisopropyl)adenosine (R-PIA) is more potent at ARs than S-PIA [@bb0085; @bb0215].

The 5′ position of AR agonists is unique in that it is situated in a small, partly hydrophilic region. There are no charged residues in this small subpocket, therefore attempts to introduce charged groups on the 5′ moiety were mostly unsuccessful. In silico fragment screening by Katritch and coworkers identified high scoring hits, of which we were able to synthesize 23 molecules [@bb0080]. Nearly all of the uncharged synthetic hits, including some novel 5′-amides that were not previously envisioned as AR ligands, bound to the A~2A~AR with micromolar affinity or better. Some of the hits were greatly enhanced in A~1~AR affinity, which was explained structurally.

3.2. A Novel A~1~ Agonist for Suppression of Seizures {#s0025}
-----------------------------------------------------

More detail about the fit of a novel selective A~1~AR agonist in the N^6^ region is shown using small cycloalkyl rings on this substituent. We chose the 4′-truncated (N)-methanocarba series because of its compactness, steric constraint, and increased hydrophobicity for the design of novel A~1~AR agonists, and incorporated many hydrophobic N^6^ substituents that were known to be A~1~AR-enhancing in the ribose series. The only substituent that maintained A~1~AR selectivity and full efficacy in this truncated series was the dicyclopropylmethyl group [@bb0215]. This A~1~AR-selectivity in the truncated 2-chloro-(N)-methanocarba series was not general across all enhancing N^6^ groups identified in the riboside series; for example, the 4′-truncated equivalent of A~1~AR agonist 2-chloro-*N*^6^-cyclopentyladenosine (CCPA **31**, structure not shown) was not A~1~AR-selective. In fact, a tight fit of the N^6^ group in the outer portion of the receptor surrounding the exocyclic amine seemed to be important for potency and efficacy, especially in the 4′-truncated series to compensate for the missing anchoring effect of the ribose 5′-region. Thus, MRS5474 **37** ([Fig. 4](#f0020){ref-type="fig"}A), bearing a *N*^6^-dicyclopropylmethyl group, is a structural sweet spot with respect to the SAR in this series, because of its balance of full agonism and modest selectivity at the human A~1~AR (K~i~ 47.9 nM).

We wondered if the more drug-like physicochemical properties of MRS5474 **37** (smaller size, fewer H-bonding donors and acceptors, less polar surface area) with respect to the prototypical A~1~AR agonists, such as CPA **1** and CCPA **31**, would alter its in vivo activity, especially activity in the brain. Use of an A~1~AR agonist to control seizures has long been a goal of CNS research in the purinergic field, but progress has been hampered by the toxicity associated with the other agonists [@bb0225]. However, MRS5474 **37** was found to reduce electrically-induced seizures in the 6 Hz minimal clonic seizure test in mice without the usual toxicity of A~1~AR agonists. In fact, a maximum tolerated dose (MTD) study in mice of this agonist revealed that doses up to 60 mg/kg (40-fold higher than the effective anti-seizure dose in mice) were not lethal.

3.3. A Rationally Designed A~2A~ Agonist for Irreversible Inhibition of the Receptor {#s0030}
------------------------------------------------------------------------------------

Irreversibly binding ligands of GPCRs are useful as pharmacological tool compounds and in some cases as therapeutic agents. We wondered if we could rationally design a chemically reactive agonist based on the position of a reactive group when the ligand was docked to the A~2A~AR X-ray structure. A series of active ester derivatives **38**--**40** was synthesized, in which a reactive *o*-nitro ester was incorporated on an elongated C2 chain ([Fig. 5](#f0025){ref-type="fig"}) [@bb0230]. The ester was intended to acylate a nucleophilic amino group in the extracellular regions of the receptor. This is also a useful structural probe, because the role of the ELs in receptor binding and activation is not entirely clear. The ELs are highly flexible regions of most GPCRs, and perhaps plasticity of these regions could induce or otherwise alter the activation of the receptor. Even though the business surface of the receptor for contacting the G protein (cytosolic sides of TMs 3, 5 and 6) or arrestin (cytosolic sides of TMs 1, 2 and 7) was clearly distinct from the ELs [@bb0205], conformational effects from the ELs could be propagated along the length of the helices to the intracellular side.

Mutagenesis results indicated that the irreversible loss of receptor binding induced by acetyl ester MRS5854 **38** was dependent on the presence of Lys153, but not Lys150 (both of which are in the region of EL2 where the active ester is predicted to be located). The amino group of Lys153 is predicted to lie closer to the reactive carbonyl of MRS5854 than Lys150 ([Fig. 5](#f0025){ref-type="fig"}). Thus, we have designed a chemically reactive agonist ligand based on structural insights.

3.4. Design of Highly Specific A~3~ Agonists Can Be Interpreted Structurally {#s0035}
----------------------------------------------------------------------------

Some reports have detected dose-dependent activity of the prototypical agonists of the A~3~AR, such as **11** and **13**, at other AR subtypes in vivo [@bb0235]. Thus, there is a need for the introduction of more highly selective A~3~AR agonists. The SAR of (N)-methanocarba nucleosides acting at the A~3~AR was explored, resulting in consistently high affinity and selectivity at the A~3~AR upon combination with favorable N^6^ groups, such as methyl or substituted benzyl, and a rigid C2-arylethynyl substituent. The combination of these substituents provides a general class of highly specific agonists, in which the A~3~AR is consistently in the nM range and the affinity at other AR subtypes is almost always \> 10 μM. One example that had a K~i~ value of 3 nM at both human and mouse A~3~ARs, MRS5698 **9** ([Fig. 2](#f0010){ref-type="fig"}B), contains difluoro substitution of the terminal phenyl ring intended to reduce oxidative metabolism in vivo [@bb0135].

In order to accommodate such rigid C2 substituents and maintain other conserved interactions of ribose and adenine with the receptor ([Fig. 6](#f0030){ref-type="fig"}), we used molecular modeling of the A~3~AR to propose an outward movement of TM2. This proposed receptor plasticity is not an arbitrary rearrangement; rather it is based on similarity to several other active-like state structures of GPCRs. Thus, a hybrid homology model was constructed, which was based on the active state of the A~2A~AR with respect to TMs 1 and 3--7 and on the active state of rhodopsin, i.e. opsin, with respect to TM2. The doubly extended biaryl derivative MRS5679 **25** required an outward movement of TM2 by \~ 7 Å. The reason that a similar rearrangement of TM2 cannot occur in the A~2A~AR is that there are a total of 3 disulfide bridges that further constrain the movement on the outer loop region of the receptor.

Sulfonate groups are a means of preventing passage across biological membranes, because of a permanent negative charge at physiological pH. In 1994, we attempted empirically to introduce a sulfonate on the prototypical riboside analogues, such as IB-MECA **11**. The effort failed; introduction of an *m*- or *p*-sulfonate group on the *N*^6^-benzyl group and greatly reduced the affinity at the rA~3~AR --- from the nM to the μM level. Instead, we recently used a structure-based approach to design a pharmacological probe to distinguish central and peripheral effects of A~3~AR agonists [@bb0140]. Selectivity of \> 3000-fold at both the human and mouse A~3~ARs was achieved with *m*-sulfophenyl analogue **23** (MRS5841, [Fig. 2](#f0010){ref-type="fig"}B), but a sulfonate in the *p*-position **24** produced a potent and selective mixed agonist of A~1~ and A~3~ARs. Thus, there is a strong dependence of the affinity on distal interactions between the ligand and the EL regions of the receptor, and we predicted specific interactions with polar and hydrophobic residues based on ligand docking to homology models of the human and mouse A~3~ARs.

3.5. Polypharmacology of AR Ligands {#s0040}
-----------------------------------

The analysis of off-target activities of new drug candidates is an essential component of drug discovery. With the design of rigid nucleoside congeners that bind to the ARs and now the availability of many GPCR structures, we have used this as a test case to quantify and possibly predict the likelihood of specific off-target (non-AR-related) activities in a systematic approach. In some cases these activities would be considered undesirable and would have to be eliminated, and other off-target activities that might synergize with the desired AR activity could be accentuated.

We analyzed the polypharmacology of otherwise 'selective' A~3~AR ligands at off-target GPCRs and other receptors [@bb0100]. Increased conformational rigidity of A~3~AR agonists and adenine antagonists allows the exploration of interaction of specific regions of the ligands with other GPCRs that have structural information (either by direct X-ray determination or by molecular modeling), such as biogenic amine receptors. A series of highly rigidified congeners (**7**--**10**, **32**--**37**) was assembled for probing off-target effects experimentally and correlating these findings with GPCR structures ([Fig. 4](#f0020){ref-type="fig"}). The ten compounds submitted to the Psychoactive Drug Screening Program (PDSP) at the University of North Carolina are indicated, and K~i~ values of binding hits (defined as \> 50% inhibition at 10 μM in the single point screen) were determined. The structural analysis was conducted at various GPCRs that turned up as hits in the screen. We present here the example of α~2~ adrenergic receptors, although a similar analysis was performed at β-adrenergic, serotonergic receptors and other GPCRs. The patterns of off-target binding often correlated with specific moieties on the molecules, which were predicted to be essential for binding at those receptors using molecular docking. As predicted, when the *N*^6^-benzyl group (viewed as a deep anchor in the α~2~ adrenergic receptors) was omitted in subsequent analogues, this off-target activity disappeared. The conserved Asp (3.32) that serves as the counterion for biogenic amines in their GPCRs, changed to a H-bonding role in the predicted recognition of adenosine congeners at the same receptors.

3.6. A~3~ Agonists for Inflammatory Diseases, Cancer and Chronic Neuropathic Pain {#s0045}
---------------------------------------------------------------------------------

The action of A~3~AR agonists in disease models is pleiotropic [@bb0240], and diverse therapeutic applications are envisioned. Can-Fite Biopharma has advanced IB-MECA **11** to Phase 2 and 3 clinical trials for autoimmune inflammatory diseases, including psoriasis and rheumatoid arthritis, A~3~AR agonists effectively reduce tumor size in several animal models [@bb0245], and Cl-IB-MECA **13** has progressed to Phase 2 clinical trials for hepatocellular carcinoma [@bb0250]. Also, an imidazoquinolinamine allosteric enhancer of the A~3~AR [@bb0255] is being proposed for treatment of inflammatory diseases by Can-Fite.

The mechanisms involved in the actions of A~3~AR agonists in disease models have been summarized by Fishman et al. [@bb0245]. In cancer and inflammation, the A~3~AR is upregulated in the affected tissue. This pathological level of receptor expression, which can often be determined by measuring the A~3~AR level in peripheral blood mononuclear cells, is also predictive of a patient\'s response to an A~3~AR agonist. Activation of the A~3~AR appears to correct imbalances in the downstream signaling pathways leading to changes in transcription in the nucleus. In models of in vivo inflammation, A~3~AR agonists have an anti-inflammatory effect by reducing activation of NF-κB (in synoviocytes, neutrophils and other immune cells), in part by reducing the expression of TNF-α.

In cancer, an A~3~AR-agonist-induced decrease in expression or activity of NF-κB could reduce its antiapoptotic effect. Activation of the A~3~AR also corrects an imbalance in the Wnt signaling pathway. cAMP inhibition indirectly decreases phosphorylation (and therefore decreased inactivation) of the serine/threonine kinase GSK-3β. The resulting increased phosphorylation of β-catenin allows it to be removed from the cytoplasm by ubiquitination, and its reduced action in the nucleus leads to suppression of cyclin D1 and c-myc and consequently cell growth inhibition. Effects of A~3~AR activation on downstream signaling can also be in opposite directions. For example, its myeloprotective effect is accompanied by increased NF-κB in splenocytes.

Together with collaborator Daniela Salvemini, we have demonstrated that A~3~AR agonists, including prototypical and novel ligands that are highly selective for this receptor subtype, are effective in suppressing and preventing chronic neuropathic pain [@bb0260]. The chronic constriction injury (CCI) model of neuropathic pain in mice was used to screen dozens of analogues in vivo. The prototypical A~3~AR agonist IB-MECA and the hypermodified MRS5698 **9** were both highly potent and efficacious in this model when administered intraperitoneally or orally, with effective doses well below 1 mg/kg in the mouse. There are both peripheral and central components to this action, as indicated using the nonpermeant MRS5841 **23** [@bb0140]. Both reversal of mechanoallodynia and hyperalgesia were observed. The necessity for A~3~AR agonism was demonstrated using the selective AR antagonists and A~3~AR^−/−^ mice. The potency of A~3~AR agonists was greater than other pain medications. Also, A~3~AR agonists do not develop analgesic tolerance [@bb0265].

4. Novel P2Y Receptor Ligands {#s0050}
=============================

There has been much recent progress in the design of selective P2YR ligands [@bb0210; @bb0270; @bb0275; @bb0280; @bb0285; @bb0290; @bb0295; @bb0300]. For example, BMS and Pfizer have reported diaryl urea derivatives as potent and selective nonnucleotide antagonists of the P2Y~1~R, a target for new antithrombotic drugs [@bb0290; @bb0295]. Nevertheless, there is still a large need for improved P2YR ligands of increased stability and bioavailability. Most of the P2YR agonists are still labile phosphate derivatives. Fischer et al. have demonstrated that introduction of a boranophosphate at the α-phosphate position of P2YR agonists greatly enhances the in vivo stability [@bb0300]. Other methods of increasing the stability of phosphate groups with varying success include methylenephosphonate bridges and thiophosphates. There is a need for additional uncharged and drug-like P2Y ligands, and the hope is that structure-based approaches will solve this need in the future.

In an effort to understand the conformational factors in recognition of P2YR ligands, we applied the steric constraints of the (N)-methanocarba modification of ribose in nucleotide agonists (and P2Y~1~R antagonists) to the eight subtypes of P2Y receptors [@bb0155; @bb0210]. In most cases, the (S)-methanocarba ring was introduced for comparison. This effectively defined the conformational preference at each of the P2Y~1~-like G~q~ coupled receptors, but uncertainty remains about which rigid ring would maintain affinity at the P2Y~12~-like G~i~-coupled receptors. Among P2Y~1~-like G~q~-coupled receptors, most receptors prefer the (N)-methanocarba modification over the (S). The potency of ATP at the hP2Y~1~R was enhanced 29-fold compared to native ATP by this (N) bicyclic ribose substitution [@bb0360]. At the hP2Y~2~ and hP2Y~11~Rs, (N)-methanocarba-ATP was roughly equipotent to ATP. (S)-methanocarba-ATP (racemic) was 5- and 44-fold less potent than ATP at the P2Y~1~ and P2Y~2~Rs, respectively. (N)-methanocarba-UTP was \~ 2-fold less potent than UTP at the P2Y~2~ and P2Y~4~Rs. Only the UDP-responsive G~q~-coupled P2Y~6~R prefers the (S)-conformation of ribose; the preference is so strong that the (N)-methanocarba UDP analogue is completely inactive, while the (S)-methanocarba UDP analogue is 7-fold more potent than UDP. Thus, the identical ribose conformational preference is not maintained throughout the evolution of the P2YR family.

4.1. P2Y~6~ Agonists for Diabetes and Fluorescent P2Y~6~ Agonists {#s0055}
-----------------------------------------------------------------

The protective effects of activation of P2Y~6~R against TNF-α were first shown in P2YR-expressing astrocytoma cells. P2Y~6~R activation protects pancreatic islet cells from apoptosis and stimulates glucose-dependent insulin release [@bb0305; @bb0310] and in insulin target tissues increases glucose uptake (unpublished). These actions involve the enzyme 5′-AMP-activated protein kinase (AMPK), a metabolic regulator that is a target for treatment of type 2 diabetes. We have used a potent and somewhat (12-fold vs. P2Y~2~R) selective P2Y~6~R dinucleotide agonist P^1^-(uridine 5′-)-P^3^-(*N*^4^-methoxycytidine 5′-)triphosphate (MRS2957, **41**, structure not shown), which is more stable than most simple UDP analogues to the action of ectonucleotidases. In MIN6 β-islet cells, treatment with MRS2957 (500 nM) activated AMPK, which was blocked by P2Y~6~R-selective antagonist *N*,*N*″-1,4-butanediyl-*bis-*\[*N*′-(3-isothiocyanatophenyl)\]thiourea (MRS2578). Also, MRS2957 induced phosphorylation of acetylcoenzyme A carboxylase (ACC), a marker of AMPK activity [@bb0305]. We attenuated P2Y~6~R-mediated AMPK phosphorylation pharmacologically to reveal involvement of intracellular Ca^2 +^ pathways. P2Y~6~R agonist induced insulin secretion at high glucose, which was also reduced by AMPK siRNA. The pharmacological agents used to block key steps in the P2Y~6~R-induced signaling cascade were: calcium chelator BAPTA-AM, calmodulin-dependent protein kinase kinase (CaMKK) inhibitor STO-069 and IP~3~ receptor antagonist 2-APB. In insulin target cells (C2C12 skeletal muscle cells and 3T3-L1 adipocytes), MRS2957 significantly increased glucose uptake compared to control, which was antagonized by MRS2578. MRS2957-treatment resulted in significant phosphorylation of AMPK in both cell lines, which was abolished by pre-incubation with MRS2578. Also, MRS2957 (30 min incubation) increased glucose transporter GLUT4 recruitment to the cell membrane (unpublished), which was blocked by MRS2578 or AMPK inhibitor (Compound C). Our results indicate that the P2Y~6~R is involved in controlling glucose metabolism at multiple levels, and this may be mediated through AMPK signaling.

P2Y~6~R activation by UDP was identified as an autocrine process by which insulin secretion is potentiated in response to glucose [@bb0315]. Nevertheless, the use of P2Y~6~R agonists for the treatment of diabetes is not yet a practical concept for pharmaceutical development. There are detrimental effects of P2Y~6~R receptor activation, such as increased interleukin (IL) 6 and other inflammatory mediators in the lung and elsewhere [@bb0320], vasoconstriction [@bb0325] and promotion of osteoclast formation in bone [@bb0330]. Moreover, all of the known P2Y~6~R agonist ligands are nucleotide derivatives and therefore of low oral bioavailability.

We designed fluorescent conjugates of functionalized congeners that display high P2YR affinity, for characterization of these GPCRs in living cells by flow cytometry and in cell membranes. Fluorescent agonists are mostly internalized consistent with agonist-induced GPCR internalization, and this labeling is attenuated by specific P2YR ligands. Examples are 5′-diphosphate derivative MRS4129 **42** [@bb0270] and MRS4162 **43** [@bb0275] ([Fig. 7](#f0035){ref-type="fig"}A), which are fluorescent pyrimidine nucleotides, respectively, selective agonist of the P2Y~6~R (EC~50~ 9 nM, phospholipase C activation) and high affinity pan-agonist at P2Y~2~R, P2Y~4~R and P2Y~6~R (expressed in astrocytoma cells). At the end of the 60 min incubation period with astrocytoma cells expressing the P2Y~6~R, the fraction of fluorescence of MRS4129 associated with the internalized label was much greater (77% of the total binding) than the fraction on the cell surface (17% of the total binding).

The point of chain extension from which to tether the fluorophore was a 4-alkyloxoimino group on the pyrimidine ring. This group preserves the double bond character of the 4 substituent of the nucleobase, which favors receptor recognition by analogy to the 4-carbonyl group of uracil. A previous attempt to extend substituents through a pyrimidine 4-thioether failed to maintain P2YR activity (e.g. a 4-hexylthio-UDP equivalent was 10-fold less potent than UDP at the P2Y~6~R) [@bb0335]. In both cases, the fluorophores were conjugated by \[2 + 3\] click cycloaddition chemistry between an alkynyl group on the pharmacophore and an azide on the fluorophore (AlexaFluor488 for MRS4129 and BODIPY for MRS4162).

4.2. Receptor Docking and Chemical Modification of a P2Y~14~ Antagonist {#s0060}
-----------------------------------------------------------------------

Both UDP-glucose (UDPG) and UDP are cognate agonists of the G~i~-coupled P2Y~14~R [@bb0340]. In collaboration with Harden, Vsevolod Katritch and others, we explored the SAR of P2Y~14~R antagonists based on potent and highly selective 4-((piperidin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2)-naphthoic acid (PPTN **44**, K~B~ = 0.434 nM in antagonizing the cAMP effects of UDPG) [@bb0285], which was originally reported by Merck [@bb0280]. Unfortunately, PPTN displays low oral bioavailability, and additional P2Y~14~ antagonists will be needed. The lack of effect up to 10 μM PPTN at the other G~q~-linked P2YRs was shown [@bb0285]. At G~i~-coupled P2YRs, there was no inhibitory effect of PPTN up to 1 μM. This 2-naphthoic acid derivative inhibited UDPG-promoted chemotaxis in HL-60 cells and in human neutrophils, suggesting application of such antagonists in inflammation. Activation of the P2Y~13~R and the P2Y~14~R in mast cells promotes degranulation, suggesting application of P2Y antagonists for the treatment of asthma [@bb0345].

We designed the first fluorescent ligand of the P2Y~14~R, i.e. the AlexaFluor488-labeled antagonist MRS4174 **45** ([Fig. 7](#f0035){ref-type="fig"}B) [@bb0350]. This compound contained a functionalized chain at the secondary nitrogen of the piperidine ring, a site that was chosen based on ligand docking at a P2Y~14~R homology model. An azide-bearing fluorophore was conjugated to an alkyne-functionalized antagonist intermediate by \[2 + 3\] click cycloaddition chemistry. We modeled the hP2Y~14~R based on the recent 2-MeSADP-bound hP2Y~12~R X-ray structure and simulated antagonist docking, which suggested that the piperidine N of PPTN is accessible for tethering fluorophores. Click chemistry was used to conjugate functionalized PPTN alkyne derivatives and azide-bearing fluorophores. Flow cytometry showed high specific P2Y~14~R binding of MRS4174 **45** with exceptionally high affinity (K~i~ 80 pM, in antagonizing UDPG-induced cAMP inhibition in P2Y~14~R-expressing CHO cells). Known P2Y ligands inhibited cell labeling consistently with affinity order. Thus, the utility of MRS4174 has been validated initially, but additional methods optimization will be needed to utilize this compound in a routine assay.

5. Conclusions {#s0065}
==============

Numerous therapeutic concepts are associated with selective modulation of ARs and P2YRs. We used chemical synthesis and molecular modeling based on X-ray structures to explore novel ligand discovery at adenosine receptors and P2Y receptors. X-ray structures of agonist-bound and antagonist-bound P2Y~12~R establish binding modes and detect conformational changes involved in activation, especially in the extracellular loop region. Thus, the 3D knowledge of receptor binding and activation is facilitating drug discovery at GPCRs that respond to extracellular nucleosides and nucleotides. However, its use as a primary tool in predicting the pharmacological profile of proposed new ligands is not yet realized. Future X-ray structures to reveal the structures of other receptors or the already crystallized receptor with novel ligands and the development of more systematic in silico methods will be required.

The ARs are well established as medicinal chemical targets with many selective agonists and antagonists. A~3~AR agonists have proven more beneficial in disease models (such as autoimmune inflammatory diseases and cancer) than A~3~AR antagonists. The A~3~AR selectivity of prototypical agonists has been improved using a structure-based design approach. A constrained ribose substitution in the North (N) conformation enhances A~3~AR affinity and selectivity, which leads to a general class of highly specific agonists. Off-target activity was probed structurally. Conformational plasticity of the A~3~AR is predicted to accommodate rigid C2 extension, leading to C2 arylethynyl analogue MRS5698, which protects against chronic neuropathic pain. At the antiepileptic A~1~AR, a compact, truncated selective agonist MRS5474 that does not produce the toxicity associated with prototypical A~1~AR agonists is suggested for reducing seizures. With the multiplicity of effects and sites of distribution of the P2Y receptors, their application to disease treatment (with the exception of antithrombotic P2Y~12~R antagonists) is still more exploratory. P2Y~6~R agonists have beneficial effects in the pancreas and in insulin target tissues, suggestive of possible application to diabetes. We reported the first fluorescent ligand of a P2Y receptor: MRS4129, which is selective and potent nucleotide agonist of the P2Y~6~R. Fluorescent agonists MRS5218 (A~3~AR), MRS4129 and MRS4162 (P2Y~6~R and other subtypes) and fluorescent antagonist MRS4174 (P2Y~14~R) are useful probes to characterize specific receptors expressed in living cells using flow cytometry and other methods.
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![Agonist-bound crystallographic structures of A~2A~AR (PDB ID: [3QAK](pdb:3QAK){#ir0015}, bound to UK432097) [@bb0035] and P2Y~12~R (PDB ID: [4PXZ](pdb:4PXZ){#ir0020}, bound to 2-MeSADP) [@bb0045]. Overall structure of the receptors and details of the binding sites. Transmembrane helices are colored from blue (TM1) to red (TM7). Ligands are shown in CPK representation with colors that indicate: the nucleobase (magenta), the ribose moiety (blue), the N^6^ and C2 substituents (yellow) and the phosphate groups (red). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr1){#f0005}

![Progression of structural changes in adenosine derivatives leading to enhanced A3AR selectivity [@bb0135; @bb0140; @bb0175; @bb0180; @bb0215]. Binding K~i~ values at the human A~3~AR using **12** as radioligand are given in italics (nM). A. Successive structural changes leading to hypermodified (N)-methanocarba analogues. 4′-Truncation was performed in the ribose, thioribose and (N)-methanocarba series with the general observation that affinity but not efficacy at the A~3~AR was maintained. A~3~AR antagonist **19** was shown to be useful in lowering interocular pressure in glaucoma models [@bb0175]. Compounds **12** (nonselective) and **22** (A3AR-selective) are useful high affinity radioligands for routine binding assays. Compounds **16** and **21** are demonstrated to be useful radioligands for positron emission tomography (PET) [@bb9000]. B. Extension of the C2 position with rigid arylethynyl substituents.](gr2){#f0010}

![A. A comparison of nucleotide agonist-bound and non-nucleotide antagonist bound P2Y12R structures [@bb0040; @bb0045]. The binding site contracted on the extracellular side of the TMs in the P2Y~12~R--2MeSADP **30** structure (green) in comparison to the complex with antagonist AZD1283 **29** (purple, PDB ID: 4NTJ). Only one nonnucleotide--P2Y~12~R complex has been determined so far; it is not known if this structure generalizes for other nonnucleotide antagonists. B. Side view of the superposed nucleotide agonist-bound and non-nucleotide antagonist-bound P2Y~12~R structures with surfaces showing the binding site shape. The P2Y~12~R--2MeSADP structure is shown in green ribbons with the associated binding site surface in cyan. The P2Y~12~R--AZD1283 structure is shown in magenta ribbons with the associated binding site surface in pink. The two subpockets of the bifurcated binding pocket are indicated as **1** (principle location of both ligands) and **2**. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr3){#f0015}

![Representative data from a study of polypharmacology of otherwise selective AR ligands. A. Shown are six of the rigid congeners that are known to bind selectively to the A~3~AR [@bb0100] or in one case to the A~1~AR [@bb0215] and that were subjected to binding and structural analysis of off-target sites, including many GPCRs. Four other rigid congeners were included in this study: truncated compounds **7**--**10** in [Table 1](#t0005){ref-type="table"}. Orange flash arrows indicate the position of truncation. B. As an example, binding affinity at three G~i~-coupled α~2~ adrenergic receptors and structural analysis by docking to antagonist-bound receptor structures are shown [@bb0100]. Left side: adenines **8** (cyan carbons) and **10** (yellow carbons) at the α~2B~ receptor; right side: adenines **8** (cyan carbons) and **10** (yellow carbons) and adenosine derivative **9** (orange carbons) at the α~2C~ receptor. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr4){#f0020}

![Targeted covalent modification of the A~2A~AR: Tethering of a reactive group to reach a distal site. Irreversible loss of receptor binding by MRS5854 **38** was associated with the presence of K153, but not K150 (both circled). B~max~ values are in pmol/mg protein [@bb0230].](gr5){#f0025}

![Predicted outward movement of TM2 of A~3~AR to accommodate a rigid aryl ethynyl extension at the adenine C2 position (example shown for a biaryl derivative, selective full agonist MRS5679 **25** in cyan). A hybrid A~3~AR model containing TM2 based on the opsin structure was required for docking. The other TMs were based on the A~2A~AR agonist bound structure [@bb0035; @bb0135]. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr6){#f0030}

![A. Fluorescent agonist ligands **42** and **43** (as salts) with high affinity, variably, for P2Y~2~R, P2Y~4~R and P2Y6R [@bb0270; @bb0275]. The colors range from the charged phosphate (brown) to the green nucleoside moiety, to the spacer (blue) and the fluorophore (violet). B. High affinity P2Y~14~R fluorescent antagonist ligand **45** (K~i~ = 80 pM, antagonist activity measured in hP2Y~14~R-expressing CHO cells) [@bb0350] in comparison with its structural lead PPTN **44** (as HCl salt). The colors indicate the pharmacophore (black), a spacer (blue) and the fluorophore (green). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr7){#f0035}

###### 

Representative examples of the combination of address (adenine) and message (ribose or ribose-like) moieties in nucleoside ligands of various ARs. Binding affinity (K~i~, nM) of corresponding adenosine agonist (I) and adenine antagonist (II) derivatives at three subtypes of ARs is shown, to examine the question whether SAR is parallel in the two series. The selectivity column refers to the complete nucleoside derivative (address + message). The affinity was measured for this study, using standard radioligand binding assays. The species is human unless noted (r, rat).

  Selectivity   I. Address + message (with ribose)   II\. Address (lacking ribose)   References
  ------------- ------------------------------------ ------------------------------- --------------------
  A~1~AR        **1**, **CPA**                       **2**                           [@bb0120; @bb0220]
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  A~2A~AR       **3**, **PEA**                       **4**                           [@bb0105; @bb0115]
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  Mixed         **5**                                **6**                           [@bb0115; @bb0355]
  ![](t5.gif)   ![](t6.gif)                                                          
  A~3~AR        **7**, **MRS3558**                   **8**, **MRS5930**              [@bb0100]
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  A~3~AR        **9**, **MRS5698**                   **10**, **MRS5923**             [@bb0140]
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